Funding for this research was provided by:
Rigshospitalet (FF22opdt.020522)
Novo Nordisk Fonden (NNF22OC0079013)
Copenhagen University
Article History
Received: 16 November 2023
Accepted: 14 January 2024
First Online: 20 February 2024
Declarations
:
: René Horsleben Petersen reports speaker fee from Medtronic, Medela, AstraZeneca and AMBU, advisory board member for AstraZeneca, MSD, BMS and Roche. Lin Huang and Henrik Kehlet have no conflict of interest to report.